Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 1/20 | 0.60 |
| ▸ | PARP1 | P09874 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.39 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | DRD1 | P21728 | 2/20 | 0.37 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.34 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.34 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.34 |
| ▸ | DRD5 | P21918 | 1/20 | 0.34 |
| ▸ | DRD3 | P35462 | 1/20 | 0.34 |
| ▸ | KIF11 | P52732 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3672464 | 1.00 | HTR2A (0.60) | HTR2APARP1MEN1CYP3A4CYP2D6 | |
| SCHEMBL16938669 | 1.00 | HTR2A (0.60) | HTR2APARP1MEN1CYP3A4CYP2D6 | |
| SCHEMBL29383346 | 1.00 | HTR2A (0.60) | HTR2APARP1MEN1CYP3A4CYP2D6 | |
| SCHEMBL22953388 | 0.85 | HTR2A (0.43) | HTR2APARP1MEN1CYP3A4CYP2D6 | |
| SCHEMBL22952986 | 0.82 | PARP1 (0.46) | HTR2APARP1CYP3A4DRD2DRD1 | |
| SCHEMBL22953390 | 0.76 | HTR2A (0.36) | HTR2APARP1DRD2DRD1KIF11 | |
| Hydrochloric Acid SCHEMBL29960806 | 0.74 | HTR2A (0.97) | HTR2AMEN1CYP3A4CYP2D6KMT2A | |
| SCHEMBL6345215 | 0.74 | HTR2A (0.46) | HTR2APARP1MEN1CYP3A4CYP2D6 | |
| SCHEMBL29383649 | 0.74 | HTR2A (0.46) | HTR2APARP1MEN1CYP3A4CYP2D6 | |
| SCHEMBL22952989 | 0.73 | PARP1 (0.43) | HTR2APARP1CYP3A4KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DARPHARMA, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DARPHARMA, INC. | 2010-02-18 | — | — | US | disclosed |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | DARPHARMA, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | DARPHARMA, INC. (US) | 2007-11-01 | — | — | US | disclosed |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DARPHARMA, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DARPHARMA, INC. (US) | 2007-07-05 | — | — | US | disclosed |
| EP-1414457-B1 | CHIRAL DINAPSOLINE | PURDUE RESEARCH FOUNDATION (US) | 2007-06-20 | — | — | EP | disclosed |
| US-7091212-B2 | Chiral dinapsoline | PURDUE RESEARCH FOUNDATION (US) | 2006-08-15 | — | — | US | disclosed |
| US-6916832-B2 | Chromeno[4,3,2-de]isoquinolines as potent dopamine receptor ligands | UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 2005-07-12 | — | — | US | disclosed |
| US-20050080266-A1 | CHROMENO[4,3,2-DE]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2005-04-14 | — | — | US | disclosed |
| US-20040063741-A1 | Chiral dinapsoline | SIT SING-YUEN (US) | 2004-04-01 | — | — | US | disclosed |
| US-6645975-B1 | Reducing, deprotecting and optionally alkylating chemical intermediates to form 8,9-dihydroxy-2,3,7,11b-tetrahydro-1H-naphtho(1,2,3-de)isoquinoline, used as dopamine receptor agonists | PURDUE RESEARCH FOUNDATION | 2003-11-11 | — | — | US | disclosed |
| EP-1192161-B1 | CHROMENO[4,3,2-DE]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS | PURDUE RESEARCH FOUNDATION (US) | 2003-05-21 | — | — | EP | disclosed |
| US-6413977-B1 | D1 AGONISTS; CENTRAL AND PERIPHERAL NERVOUS SYSTEM DYSFUNCTIONS; IMPROVING COGNITION AND MEMORY; PARKINSON'S DISEASE, SCHIZOPHRENIA, ATTENTION-DEFICIT HYPERACTIVITY, SUBSTANCE ABUSE, PHYSIOLOGICAL FUNCTION | PURDUE RESEARCH FOUNDATION | 2002-07-02 | — | — | US | disclosed |
| EP-0845988-B1 | NOVEL FUSED ISOQUINOLINES AS DOPAMINE RECEPTOR LIGANDS | PURDUE RESEARCH FOUNDATION (US) | 2001-12-05 | — | — | EP | disclosed |
| US-6194423-B1 | CENTRAL NERVOUS SYSTEM DISORDERS | PURDUE RESEARCH FOUNDATION | 2001-02-27 | — | — | US | disclosed |
| US-5959110-A | SUBSTITUTED TETRAHYDRO-1H-NAPH(1,2,3-DE)ISOQUINOLINE COMPOUND USEFUL FOR TREATING NERVOUS SYSTEM DISORDERS | PURDUE RESEARCH FOUNDATION (US) | 1999-09-28 | — | — | US | disclosed |
| EP-0845988-A4 | NOVEL FUSED ISOQUINOLINES AS DOPAMINE RECEPTOR LIGANDS | PURDUE RESEARCH FOUNDATION (US) | 1998-11-11 | — | — | EP | disclosed |
| EP-0845988-A1 | NOVEL FUSED ISOQUINOLINES AS DOPAMINE RECEPTOR LIGANDS | PURDUE RESEARCH FOUNDATION (US) | 1998-06-10 | — | — | EP | disclosed |
| WO-1997006799-A1 | NOVEL FUSED ISOQUINOLINES AS DOPAMINE RECEPTOR LIGANDS | PURDUE RESEARCH FOUNDATION (US) | 1997-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041690-A1 | Co-Administration of Dopamine-Receptor Binding Compounds | DRD2, DRD1, DRD3 | HTR2A 17/4885PARP1 2956/4885MEN1 3906/4885 |
| US-20070254906-A1 | Method of Administration of Dopamine Receptor Agonists | ADRA1D, DRD2, CHRM3 | HTR2A 51/4885PARP1 2962/4885MEN1 4494/4885 |
| US-20050080266-A1 | CHROMENO[4,3,2-DE]ISOQUINOLINES AS POTENT DOPAMINE RECEPTOR LIGANDS | DRD2, COMT, CHRM3 | HTR2A 22/4885PARP1 3687/4885MEN1 4885/4885 |
| US-20040063741-A1 | Chiral dinapsoline | NAP1L1, DDAH1, NAP1L4 | HTR2A 49/4885PARP1 967/4885MEN1 2071/4885 |
| US-20070155720-A1 | Co-administration of dopamine-receptor binding compounds | DRD2, DRD1, DRD3 | HTR2A 17/4885PARP1 2944/4885MEN1 3893/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.